Editorial policy and the reporting of randomized controlled trials: a survey of instructions for authors and assessment of trial reports in Indian medical journals (2004-05).

BACKGROUND: Many international journals require authors of randomized controlled trials to adhere to standards of reporting described in the statement of the Consolidated Standards of Reporting Trials (CONSORT) and the requirements issued by the International Committee of Medical Journal Editors (ICMJE). We examined the extent to which these international standards have been adopted by Indian medical journals. METHODS: To identify Indian medical journals that publish randomized controlled trials, we did electronic searches of the websites of the National Informatics Centre (Indian Medlars Centre), Database of Open Access Journals, National Library of Medicine, WHO's Index Medicus for the South-East Asian region and Google. We analysed their instructions to authors for endorsement of the CONSORT statement and the ICMJE requirements for reporting of randomized controlled trials. We then identified all randomized controlled trials published in these journals during 2004 and 2005 and assessed them against selected CONSORT items and ICMJE requirements, and scored them on the Jadad scale. RESULTS: Of the 65 journals selected, 38 (58.5%) mentioned the ICMJE requirements in their instructions for authors but only 20 (31%) specifically required authors to submit manuscripts in accordance with the CONSORT statement. Of 151 randomized controlled trials published during 2004-05, only 4 of 13 (30.8%) selected CONSORT items were reported in > 50% of trial reports. Items reflecting internal validity were poorly reported. Jadad scores were significantly higher for general medical journals compared with specialty journals (mean difference 0.46; 95% CI: 0.15-0.78; p = 0.005) and in trials published in 2005 over those published in 2004 (mean difference 0.48; 95% CI: 0.18-0.79; p = 0.002). Ethical issues were poorly reported in one-third of reports, and sources of funding and conflicts of interest were not declared in over three-fourths. Adequacy of reporting was not related to endorsing either the CONSORT statement or the ICMJE requirements. CONCLUSION: Medical journals published in India should adopt internationally recognized norms for reporting clinical trials and work with authors, reviewers and institutional review boards to improve the standards of conduct, reporting and validity of inferences of trials.

Neuromyotonia: clinical profile of twenty cases from northwest India.

OBJECTIVES: We are presenting 20 cases of the intriguing clinico-electromyographic entity, now considered a potassium channel disorder, Neuromyotonia. Our experience with the clinical manifestations, underlying abnormalities and response to various therapies is documented. MATERIALS AND METHODS: Patients with diffuse pain or undulating muscle movements, with or without stiffness were sent for electromyographic and further studies. Patients with "neuromyotonic discharges" were included after exclusion of hypocalcaemia. RESULTS: Our cases included 19 males and one female of age group 15 to 52 years, the majority being between 30 to 45 years. Undulating movements were seen in 19, of which two had focal twitching. Muscle stiffness was a complaint in five; pain was the chief presenting complaint of 19, which started in the calf in all. Irritability, insomnia and a peculiar worried pinched face were present in 12 patients. CSF was abnormal with mildly raised protein in eight. Curiously, 11 of these patients had taken ayurvedic treatment for various complaints in the preceding one month. Bell's palsy was associated in four, peripheral neuropathy in two and residual poliomyelitis in two. Electromyographic evidence of spontaneous activity in the form of "neuromyotonic discharges" was seen in all. Antibodies to voltage gated potassium channels was tested in one patient and was positive (titer was 1028 pM). Membrane stabilizers (e.g, phenytoin sodium) in our experience did not provide adequate rapid relief; we tried high-dose intravenous Methylprednisolone in 19 with significant amelioration of complaints. One patient was offered intravenous immunoglobulin, to which he responded. CONCLUSIONS: Neuromyotonia is a heterogeneous condition and can present in varied ways including diffuse nonspecific pain. This uncommon condition is potentially treatable and can be picked up with high index of suspicion.

The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.

BACKGROUND: Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous infusion of prostacyclin has proved effective. However, it carries the risk of serious complications arising from the complex delivery system. Prostacyclin analogs, endothelin antagonists, and the phosphodiesterase-5 inhibitor sildenafil are emerging promising therapies. This study was aimed at evaluating the utility of oral sildenafil in patients with pulmonary hypertension of varied etiology, poorly controlled on conventional treatment. METHODS AND RESULTS: Ten consecutive patients with pulmonary hypertension, either primary or related to previous left-to-right shunts, thromboembolism, or interstitial lung disease, poorly controlled on conventional therapy such as warfarin, calcium antagonists, digitalis, and diuretics, were included. A thorough clinical, laboratory, and comprehensive echo Doppler evaluation was performed before enrollment in the trial to establish the diagnosis and obtain baseline data. Subjects received sildenafil 25 mg 8 hourly, or a matching placebo for two weeks each, in a randomized, double-blind, crossover design. A run-in period of two weeks was permitted between the two therapies during which patients continued to receive the conventional therapy without any vasodilator. At the end of each therapy period, the patients were evaluated for symptoms, New York Heart Association class, distance covered during the 6 min walk test, rating of modified Borg dyspnea score, and systolic pulmonary artery pressure using echo Doppler. The differences in the above variables at the end of sildenafil and placebo therapies were compared. Nine patients completed the study protocol. Sildenafil, compared to placebo, was associated with improved exercise tolerance as determined by the 6 min walk test (266.67+/-131.45 m v. 170+/-105 m; p<0.005), decrease in modified Borg dyspnea score (3.56+/-1.01 v. 5.11+/-1.45; p<0.01), decrease in Doppler-estimated pulmonary artery systolic pressures (55.33+/-16.52 mmHg v. 75.33+/-19.75 mmHg; p<0.005), improvement in New York Heart Association class (2 patients), and improvement in symptoms. Sildenafil was well tolerated with no untoward effects; further, no significant changes in heart rate or blood pressure occurred during the study period. CONCLUSIONS: Sildenafil improves exercise capacity and symptoms, and decreases pulmonary artery pressures in patients with primary or secondary pulmonary hypertension of varied etiology.